Business Context and Reporting Period
This Form 8-K Current Report was filed by Capricor Therapeutics, Inc. on June 4, 2019. The filing reports a corporate action involving an amendment to the Company's Certificate of Incorporation to effect a reverse stock split of its common stock.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on capital structure changes.
Material Changes
- Reverse Stock Split: The Company implemented a 1-for-10 reverse stock split effective June 4, 2019, at 5:00 p.m. Delaware time.
- Share Count Reduction: The number of outstanding common shares was reduced from approximately 34.7 million to approximately 3.5 million.
- Fractional Shares: No fractional shares were issued; holders received cash in lieu of fractional shares based on the closing price on June 3, 2019.
- Authorized Shares: The total number of authorized shares remained unchanged at 50 million.
- Adjustments: Proportionate adjustments were made to the exercise prices and share counts for outstanding stock options and future issuances under Stock Option Plans.
Guidance, Outlook, and Risks
The filing does not provide financial guidance, management commentary on future operations, or specific risk factors beyond the standard legal disclaimer that the information is qualified by the full text of the Certificate of Amendment. The Company expects trading on a reverse stock split-adjusted basis to commence on The Nasdaq Capital Market on June 5, 2019, under the symbol "CAPR" with a new CUSIP number (14070B309).
Investor Verification Checklist
- Verify the new CUSIP number (14070B309) for trading purposes.
- Confirm the adjusted share count and cash payment for fractional shares in brokerage accounts.
- Review the adjusted exercise prices and share quantities for any held stock options.
- Monitor trading volume and price on June 5, 2019, to assess market reaction to the split.